Bridging the Gap: Menin Inhibitor Handoffs From Academic to Community Pharmacy

Zepcan walks through what a complete pharmacist-to-pharmacist handoff should include when a patient with AML on a menin inhibitor moves from an academic center to community care, covering dosing history, QTc and laboratory test baselines, and documented counseling. She highlights the most common gap (missing monitoring history), agent-specific interaction flags for revumenib and ziftomenib, and the red-flag symptoms that warrant same-day follow-up rather than a wait-and-see approach.